BioTalk is a news hub brought to you by Bird & Bird's International Life Sciences & Healthcare Group. Read more about us >

Manufacturing and stockpiling waiver set to limit rights of holders of SPCs for medicines

On 17 April 2019, the European Parliament approved, by a large majority, an amendment of the Regulation on Supplementary Protection Certificates (“SPCs”). This much debated amendment, the latest version of which can be found here, introduces two new exemptions from SPC infringement for acts in relation to export-bound manufacturing and end-of-term storage of SPC protected medicinal products (the “Waiver Regulation”).

Not only manufacturing, but also stockpiling and related acts

Under the Waiver Regulation, SPC holders will no longer be able to block third parties from manufacturing (pharmaceutical) products for the purpose of exporting them to third countries. This exemption will also extend to related acts by third parties contractually involved in such production or export. The Recitals cite as examples of such related acts, inter alia, the possession, supply, offer to supply, use, synthesis of an active ingredient, temporary storage of the product, or advertising for the exclusive purpose of exporting. Importantly, the Waiver Regulation will also extend to acts of storage. The latter exemption will be limited in time to the final six months of SPC protection, as it aims to allow effective day-1 commercialisation upon expiry on the SPC.

Anti-diversion measures

To counter the risk of illicit market entries beyond the ambit foreseen by the Waiver Regulation, those benefiting from the waivers will have to comply with a series of anti-diversion measures:

  1. Notify the SPC holder and the national authority that granted the SPC right(s) concerned at least three months before any act of manufacturing or related act.
  2. Inform third parties involved in the process that the Waiver Regulation is applicable and that the given product is destined solely for export outside the EU.
  3. Label products manufactured for such export with a specific mark.

Timeframe

Subject to a final approval by the European Council, the Waiver Regulation will enter into force on the twentieth day after its publication in the Official Journal of the European Union. This is expected to occur by mid-2019. SPCs already granted and effective will not be affected by the waivers. However, SPCs that have been applied but are not yet granted and effective will be facing the waivers from the third year after the effective date of the Waiver Regulation (mid-2022).

A more elaborate analysis can be found here.

 

Written by
Domien Op de Beeck
Domien Op de Beeck
As a member of our Intellectual Property group in Brussels, I have played a key part in Bird & Bird's handling of major IP disputes here in Belgium and internationally since 2007.
Charlotte Haine
Charlotte Haine
I'm an associate in our Intellectual Property group in Brussels. I get involved on contentious and non-contentious matters concerning copyright, trademarks and other tech and non-tech IP-related matters, both in Belgium and on a pan-European basis.

Related articles

China passed new amendments to the Drug Administration Law
By Alison Wong, Emma Ren, Yang Li On 26 August 2019, China's National People's Congress passed the final...
COVID-19: ANSM guidance on Data Protection requirements for on-going trials
ANSM guidance underlines that adjustments to on-going clinical trials in the context of Covid-19...
Dutch competition authority ACM publishes a sector report on the impact of biosimilars on competition between TNF-alfa inhibitors
The Dutch competition authority, ACM, initiated a market study in 2018 into the effect of the introduction...